Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II trial (SAKK 75/06)

Journal of Clinical Oncology

Volumn 29, Issue 6, 2011, Pages 626-631

  Ruhstaller, Thomas ^a   Pless, Miklos ^a   Dietrich, Daniel ^a   Kranzbuehler, Helmut ^a   Von Moos, Roger ^a   Moosmann, Peter ^a   Montemurro, Michael ^a   Schneider, Paul M ^a   Rauch, Daniel ^a   Gautschi, Oliver ^a   Mingrone, Walter ^a   Widmer, Lucas ^a   Inauen, Roman ^a   Brauchli, Peter ^a   Hess, Viviane ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CLINICAL ARTICLE; DEHYDRATION; DEPRESSION; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HYPOMAGNESEMIA; INFECTION; LOADING DRUG DOSE; MALE; MOOD CHANGE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RADIATION DOSE; RASH; REOPERATION; SIDE EFFECT; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; VOMITING;

EID: 79952075689     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.9715     Document Type: Article

References (9)

1. Ajani JA: Carcinoma of the esophagus: Is biology screaming in my deaf ears? J Clin Oncol 23: 4256-4258, 2005
2. Ruhstaller T, Widmer L, Schuller JC, et al: Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol 20:1522-1528, 2009
3. Ribi K, Koeberle D, Schuller JC, et al: Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer 17:1109-1116, 2009
4. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
5. Safran H, Suntharalingam M, Dipetrillo T, et al: Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391-395, 2008
6. Gibson MK, Catalano PJ, Kleinberg L, et al: E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. J Clin Oncol 28:316s, 2010 (suppl; abstr 4064)
7. Mandard AM, Dalibard F, Mandard JC, et al: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: Clinicopathologic correlations. Cancer 73: 2680-2686, 1994
8. Brücher BL, Becker K, Lordick F, et al: The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106:2119-2127, 2006 (Pubitemid 43673232)
9. Agarwala AK, Hanna N, McCollum A, et al: Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. J Clin Oncol 27:216s, 2009 (suppl; abstr 4557)